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ABSTRACT 
Fifteen quinoline-2-thiosemicarbazone hybrid derivatives were synthesised in a three step 
reaction involving formation of the quinoline, oxidation of the 2-methyl group and 
condensation to the thiosemicarbazones. The phenylhydrazines were prepared in an additional 
step prior to the condensation. Twelve of the fifteen hybrid molecules were novel. A full 
structural elucidation of all synthesised compounds were carried out using amongst others 1D 
and 2D NMR spectroscopy and mass spectrometry. The data presented here will provide a 
basis for the identification of further molecules of this type.  The hybrid molecules were then 
subjected to antibacterial bioassays against Gram -ve and Gram +ve bacterial strains. 
Unfortunately, only one compound, the 6-bromo-4'-fluoro derivative on the (E)-2-quinoline-2-
yl)methylene-N-phenylhydrazinecarbothiamide framework showed any antibacterial activity.  
They were active against both Staphylococus aureus and methicillin resistant Staphylococcus 
aureus (MRSA) at 387 M.  
 
Keywords: Quinoline-2-thiosemicarbazone, antibacterial, Doebner-von Miller, structural 
elucidation 
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6a F H 6f Cl H 6k Br H 
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6c F Cl 6h Cl Cl 6m Br Cl 
6d F NO2 6i Cl NO2 6n Br NO2 
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Chapter 1. Introduction 
Since the discovery of penicillin in 1928 by Sir Alexander Fleming, antibiotics have been used 
to treat bacterial infections, preventing secondary infections and even death.  Even prior to this, 
there was evidence of antibiotics being used, with traces of tetracycline being found in human 
skeletal remains of Egyption and Sudanese Nubia populations dating back to 350-550 CE 
(Aminov, 2010).  These antibiotics have also played an important role in medicine and surgery 
preventing bacterial infections from setting in after surgery (Ventola, 2015).  However, over 
the years, overuse, inappropriate and incorrect prescribing, self-medicating and extensive 
agricultural use of antibiotics has led to antibiotic resistance (Ventola, 2015; Rather et al., 
2017). 
 
Antibiotic resistance occurs when bacteria modifies its structure and form in some way that 
reduces or eliminates antibiotic binding reducing or eliminating their effectiveness (Bisht et 
al., 2009).  As a result, resistant bacteria are able to survive and mutate, leading to bacteria that 
are not susceptible to known antibiotics.  The consequences are prolonged illnesses, greater 
risk of death, longer periods of hospitalization and an increase in infections.  A huge percentage 
of bacteria (at least 70%) has become resistant to at least one of the most commonly used 
antibiotics used for treatment (Bisht et al., 2009). 
 
To combat this problem, scientists and pharmaceutical companies have developed and 
introduced many new antibiotics.  This was rampant from 1940-1980, but significantly 
declined thereafter, largely contributing to the antibiotic resistance crisis we find ourselves in 
today (Martens and Demain, 2017).  This has been attributed to the merging of pharmaceutical 
companies, leading to less productive companies, a decline in Natural Products research, which 
inspired or contributed to the development of antibiotics and the cost involved in producing 
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these drugs (12-15 years and costing in the region of 1.2 billion US dollars) (Martens and 
Demain, 2017). 
 
However, antibiotic resistance has now become a crisis, since the rate at which these antibiotics 
are being rendered inactive due to antibiotic resistance is alarming with more and more bacteria 
becoming resistant to commonly used drugs.  For Gram positive bacteria, this has been 
described as a crisis that is under control and for Gram negative bacteria, a crisis going out of 
control (Rossolini et al., 2014).  The inactivity of current antibiotics through antibiotic 
resistance will lead to loss of human lives if alternative antibiotics are not discovered soon.  
There is thus an urgent need for the development of new antimicrobials to treat bacteria that 
have become resistant to first line antibacterial agents used in treatment.   
 
The current project aims to address this by synthesising new molecules, which have a good 
chance of having antibacterial activity and hence could be developed into alternative antibiotics 
to currently marketed drugs.  We aim to use an approach of creating hybrid molecules.  
 
Hybrid molecules are those incorporating the frameworks of two molecular scaffolds, each 
with bioactivity of their own.  These compounds contain the basic framework of each of the 
individual structures. The desired effect of the hybrid molecule is to have a synergistic effect 
between the different pharmacophores, increasing the activity of either of them alone.  The 
ultimate prize is one drug which can treat more than one disease or medical condition or 
enhance the therapeutic potential of an existing drug.   These molecules are usually formed by 
an organic reaction with two functional groups, one on each molecular framework.  Quinoline 
hybrids have produced compounds with increased bioactivity (Vandekerckhove and D'Hooghe, 
2015), for example anti-malarial (Burgess et al., 2006), antitubercular (Jain et al., 2016), 
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anticancer (Solomon et al., 2010; Alegaon et al., 2017), antileishmanial (Coa et al., 2017) and 
antimicrobial activities (Desai et al., 2013) amongst others.  Likewise, thiosemicarbazide 
hybrids have also shown good bioactivity such as antidiabetic (Taha et al., 2016), antibacterial, 
antitubercular (Rane et al., 2014) and anticancer agents (Rane et al., 2015). 
 
When a quinoline with an aldehyde or ketone substituent reacts with a thiosemicarbazide 
moiety, the hybrid molecule that forms is termed a quinoline-thiosemicarbazone. These 
quinoline-thiosemicarbazone hybrids have shown anticancer (Huang et al., 2010), 
antimicrobial (Abdel-Moty et al., 2005; Kulkarni et al., 2010), anti-oxidant  (Ramachandran et 
al., 2012), anti-HIV, antitubercular (Banerjee et al., 2010), anticonvulsant and analgesic 
activities (Aly et al., 2010).  
 
1.1 Quinolines 
Quinoline is an aromatic heterocyclic compound consisting of two fused rings, a benzene ring 
fused with a pyridine ring (Figure 1.1), and has the synonyms benzopyridine, 
benzo[b]pyridine, and benzazine. The quinoline nucleus occurs in several naturally occurring 
compounds (O'Donnell et al., 2006; Michael, 2008; Zhang et al., 2012) and pharmacologically 
active substances displaying a broad range of biological activity (Gopaul et al., 2015). These 
include antimalarial (Vandekerckhove and D'Hooghe, 2015), anti-cancer (Afzal et al., 2015; 
Gopaul et al., 2015), antioxidant (Maddela et al., 2015), anti-HIV (Luo et al., 2009), 
antimicrobial (Musiol et al., 2011), antileishmanial (Gopinath et al., 2013), antimycobacterial 




Figure 1.1 The general structure of the quinoline nucleus 
 
Several natural occurring compounds that contain the quinoline moiety are either 
pharmaceuticals or employed as lead compounds for the development of new and more potent 
drugs (Kumar et al., 2009). One such example is quinine (Figure 1.2) isolated from the bark 
of the cinchona tree, used in the treatment of malaria (Kumar et al., 2009). This initial discovery 
was followed by the development of more potent drugs such as chloroquine, primaquine and 
mefloquine (Figure 1.2) (Kumar et al., 2009).  
 
Figure 1.2  Biologically active compounds containing a quinoline nucleus 
 
Synthesis 
Many methods are used to synthesise quinolines (Yamashkin and Oreshkina, 2006; Madapa et 
al., 2008).   Most start with simple anilines and make use of electrophiles, which form a 
heterocyclic ring from their reaction.  Reactions used to synthesise quinolines include the 
Skraup, Conrad-Limpach, Combes, Pavarov, Doebner and Doebner-von Miller reaction (Li 
and Corey, 2004; Ramann and Cowen, 2016). 
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The Skraup synthesis involves anilines, such as m-toluidine reacting with glycerol in the 
presence of a sulphuric acid catalyst and nitrobenzene (an oxidising agent in the reaction) 
forming a mixture of 7-methylquinoline and 5-methylquinoline (Scheme 1-1) (Zibaseresht et 
al., 2013).   
 
 
Scheme 1-1 Skraup quinoline synthesis 
 
In the Combes synthesis, condensation of anline with β-diketones take place to form 2,4-
substituted quinolines in the presence of an acid catalyst (Scheme 1-2) (Aribi et al., 2016). 
 
 
Scheme 1-2 Combes quinoline syntheses 
 
The Conrad-Limpach synthesis conditions are like those of the Combes synthesis but uses β-
ketoesters, which results in quinolones being formed (Scheme 1-3).  A modification of this 
synthesis makes use of a vinyl ether instead of ethyl acetoacetate.  With a deactivating p-nitro 






Scheme 1-3  Conrad-Limpach quinoline syntheses 
 
 
Scheme 1-4  Conrad-Limpach quinoline syntheses making use of a vinyl ether ester 
 
Anilines reacted with substituted aldehydes and pyruvic acid forming quinoline-4-carboxylic 
acids in a reaction called the Doebner reaction (Scheme 1-5) (Wang et al., 2016).  The resultant 
quinoline products have a carboxyl group at C-4 and substituent at C-2 depending on the 
aldehyde used in the synthesis. 
 
 
Scheme 1-5  Quinoline synthesis via the Doebner reaction 
 
The Doebner-von Miller synthesis makes use of α,β-unsaturated ketones and aldehydes in the 
presence of an acid catalyst (Scheme 1-6) (Gopaul and Koorbanally, 2016).  When aldehydes 
are used, 2-substituted quinolines are formed and when ketones are used, 2,4-disubstituted 




Scheme 1-6  Doebner-von Miller quinoline synthesis  
 
In the Pavarov synthesis, condensation between an aniline and aromatic aldehyde first takes 
place forming an imine, which then undergoes a cycloaddition reaction with an alkene having 
an electron donating substituent such as ethoxyethene to form 2-phenylquinolines. This 
reaction uses boron trifluoride as a Lewis acid catalyst (Scheme 1-7) (Kouznetsov, 2009). 
 
Scheme 1-7 Pavarov quinoline syntheses  
 
This reaction proceeds by imine formation from a condensation reaction between aniline and 
benzaldehyde followed by a 2+2 cycloaddition reaction between the imine and ethoxyethene 
forming an unstable four membered ring intermediate.  Ring opening and cyclisation to a six-




Scheme 1-8  Proposed reaction mechanism for the Pavarov synthesis 
 
In the Friedlander synthesis, o-aminobenzaldehyde reacts with ketones, aldehydes or other 
carbonyl compounds containing reactive α-methylene groups to form 2,3-disubstituted 
quinoline derivatives (Scheme 1-9) (Shiri et al., 2011). 
 
Scheme 1-9  Friedlander quinoline syntheses  
  
The Niementowski quinoline synthesis is similar to the Friedlander synthesis, however instead 
of the aldehyde, a carboxylic acid group is present in the aniline derivative.  When this reagent 
is reacted with a β-diketo ester, a pseudo coumarin skeleton occurs in an angular fashion on 




Scheme 1-10  Niementowski quinoline syntheses  
 
The Pfitzinger quinoline synthesis uses isatin instead of aniline derivatives, which reacts with 
carbonyl compounds in the presence of strong bases such as potassium hydroxide.  This 
reaction produces quinolines with a carboxyl group at C-4 (Scheme 1-11) (Sangshetti et al., 
2014).   
 
Scheme 1-11  Pfitzinger quinoline synthesis 
 
In the present work, the Doebner-Miller reaction was used to synthesise quinolines since the 
design of the target molecules used crotonaldehyde as a reagent along with aniline to form 2-
methylquinolines.  This was an essential intermediate for subsequent oxidation to quinoline-2-
carbaldehyde from which thiosemicarbazones were synthesised.   
 
More about the Doebner-von Miller reaction 
This reaction is normally conducted in a biphasic solvent system consisting of toluene and 
aqueous hydrochloric acid, in order to keep nucleophiles away from the aldehyde moiety, 
preventing polymerisation of the aldehyde.  The biphasic system also helps in the isolation of 
the quinoline derivative in that the quinoline remains in the organic phase and other polar 
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compounds in the aqueous phase (Matsugi et al., 2000).  This reaction has some limitations, 
such as being limited to sterically accessible aldehydes such as crotonaldehyde.  Sterically 
bulky aldehydes such as cinnamaldehyde does not produce corresponding phenylquinolines 
under similar reaction conditions (Reynolds et al., 2010). 
 
The Doebner-von Miller reaction involves cyclization of the amino group from aromatic 
amines with α,β unsaturated compounds (Reynolds et al., 2010). The four carbon 
crotonaldehyde (an α,β-unsaturated compound)  can be formed by the reaction of two 
molecules of  acetaldehyde (Snell et al., 2010).  Aniline then condenses with crotonaldehyde 
forming an enol.  Subsequent departure of the hydroxy group after protonation results in a 
conjugated imine.  A 2+2 cycloaddition reaction of two molecules of the imine then forms a 
four-membered intermediate, which opens and cyclises to a six-membered intermediate.  After 
aromatisation is restored, one of the nitrogen atoms (that which is not adjacent to the aromatic 
ring) is then protonated, catalysing the opening of the six-membered heterocyclic ring.  
Cyclisation then occurs with the adjacent alkene moiety and the aromatic amine is then 
released.  The final step involves a dehydrogenation step to yield the quinoline (Scheme 1-12) 
(Eisch and Dluzniewski, 1989).  
 
This reaction takes place at temperatures between 80 – 111 °C (Reynolds et al., 2010; Ramann 
and Cowen, 2015) and is usually catalysed by Brønsted acids  such as hydrochloric acid 
(Gopaul and Koorbanally, 2016), sulfuric acid (Yadav et al., 2016) and heteropoly acids such 
as phosphomolybdic acid (Chaskar et al., 2010) and phosphotungstic acid (Sivaprasad et al., 
2006). Ranu et al. (2003) also demonstrated that quinolines and dihydroquinolines could be 
synthesised using solvent free microwave reactions on the surface of silica gel impregnated 
with In (III).   
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Oxidation of 2-methylquinoline to quinoline-2-carboxaldehyde 
The oxidation of 2-methylquinoline (quinaldine) to either quinoline-2-carbaldehyde or 
quinoline-2-carboxylic acid (quinaldinic acid) creates functionality at C-2 on the quinoline 
nucleus, which can be used for further nucleophilic and coupling reactions. Selenium dioxide 
(SeO2) is a commonly used oxidant for the oxidation of quinaldine to quinoline-2-
carboxaldehyde (Scheme 1-13) (Achremowicz, 1996; Pérez-Melero et al., 2004; Gopinath et 
al., 2013; Wang et al., 2015; Gopaul and Koorbanally, 2016).   
 
Scheme 1-12  Proposed mechanistic pathway for the Doebner-von Miller synthesis (Eisch 
and Dluzniewski, 1989) 
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Precautions are to be taken when working with SeO2 as it is known to be toxic and to form 
selenous acid, a severe skin irritant when in contact with the body fluids such as perspiration 
and tears (Mlochowski and Wojtowicz-Mlochowska, 2015). The oxidation was carried out in 
boiling aprotic solvents such as dioxane with yields as high as 90% (Wang et al., 2015) or 
xylene (Pérez-Melero et al., 2004) with yields of between 50 – 80%. Using SeO2 in the absence 
of reflux conditions produces yields of 70%, but only after two weeks (Achremowicz, 1996).  
 
 
Scheme 1-13  Oxidation of 2-methylquinoline to quinoline-2-carbaldehyde 
 
A much greener photo-oxidation of 2-methylquinoline (quinaldine) to quinoline-2-
carboxaldehyde in good yield (65%) was reported where the methyl group was oxidised with 
TFA and I2 by irradiation under an oxygen atmosphere for 20 hours (Nagasawa et al., 2016).  
Aerobic oxidation of 2-methylquinolines using copper catalysts in DMF at 130 °C in 12 hours 
was also carried out (Zheng et al., 2016).  Microwave assisted oxidation of methylquinolines 
to quinoline aldehydes was demonstrated using phenyliodine(III) diacetate (PIDA) as a catalyst 
in DMSO in 18 to 42 minutes (Jiang et al., 2016).  
 
Quinaldine (2-methylquinoline) can also be oxidized to quinoline-2-carboxylic acid 
(quinaldinic acid) when using selenium dioxide in dioxane refluxing for 2-8 hours (Musiol et 
al., 2009; Chandrasekhar et al., 2011) (Scheme 1-14).  An aerobic oxidation of quinaldine to 
quinaldinic acid was also carried out using N-hydroxyphthalimide 




Scheme 1-14  Oxidation of 2-methylquinoline to quinoline-2-carboxylic acid 
 
Quinoline-2-carbaldehyde was easily oxidized to quinaldinic acid  using hydrogen peroxide in 
formic acid (Dodd and Le Hyaric, 1993) or hydrogen peroxide in water catalysed by a 
sulfoxyalkyl-substituted N-heterocyclic carbene catalyst (Scheme 1-15) (Yoshida et al., 2009). 
 
 
Scheme 1-15  Oxidation of quinoline-2-carbaldehyde to quinaldinic acid 
 
Mechanism of oxidation 
In the proposed mechanism by Trump and Zhou (1993) (Scheme 1-16), nucleophilic attack by 
methylquinoline to selenium dioxide followed by proton transfer, leads to an unstable four 
membered cyclic intermediate, resulting in the oxygen adding to the 2-methyl group to open 
up the four-membered ring by breaking the C-Se bond.  In the final step, the oxygen bound to 
Se abstracts the proton from the 2-methylene group, forming quinoline-2-carbaldehyde and 
releasing selenium and water. 
 
In SeO2 oxidation of methylquinoline, Se4+ is reduced to Se, which is subsequently removed 
from the reaction mixture by filtration. The aldehyde formed is then separated by biphasic 




Scheme 1-16  Proposed mechanism for the oxidation of 2-methylquinoline by selenium 
dioxide (Trump and Zhou, 1993) 
 
1.2 Thiosemicarbazides and thiosemicarbazones 
Thiosemicarbazides are an important class of compounds, which together with their derivatives 
have good biological activity (Singhlal et al., 2013), including anticancer (Arora et al., 2014), 
antitubercular (Patel et al., 2014), antibacterial (Nevagi and Dhake, 2013), antiproliferative 
(Pitucha et al., 2016), and antifungal (Er et al., 2017) activity.  When thiosemicarbazides form 
imines with aldehydes or ketones in an additional step, the resultant molecules are termed 
thiosemicarbazones (Figure 1.3) (Singh et al., 1978). Thus, thiosemicarbazones have an 
unsaturated N-1 whereas thiosemicarbazides have a fully saturated N-1.  Thiosemicarbazones 
have shown antibacterial (Souza et al., 2013), anticancer (Thanigaimalai et al., 2012), 
antiparasitic (Glinma et al., 2014) and antioxidant activities (Nguyen et al., 2013).  
 
 
Figure 1.3  The structures of thiosemicarbazides and thiosemicarbazones 
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Thiosemicarbazones have also demonstrated their ability to complex with metal ions, such as 
Fe(II), Cu(II), Pd (II) and Zn(II) resulting in pharmaceutically active compounds (Zeglis et al., 
2011; Yu et al., 2009; Hernandez et al., 2013). The metallation has been shown to play a role 
in bioactivity such as topoiosomerase IIα inhibition and antiproliferative activity (Zeglis et al., 
2011).  Examples of commercially available thiosemicarbazone based drugs are Marboran® 
(methisazone), an antiviral used to treat smallpox, and Triapine® (3-aminopyridine-2-
carboxaldehyde thiosemicarbazone) which is an anti-cancer drug (Figure 1.4).  
 
Synthesis  
Thiosemicarbazide synthesis involves the preparation of isothiocyanates in situ by nucleophilic 
addition of amines to carbon disulfide, resulting in potassium arylcarbamodithioates.  These 
intermediates then react with methyl iodide, which replaces the potassium to afford N-aryl 
methyldithiocarbamates, which undergo hydrazinolysis to give 4-arylthiosemicarbazides 
(Scheme 1-17). They can also be formed by starting directly from isothiocyanates or 
ammonium thiocyanates which undergo a condensation reaction with carbohydrazines 
(Scheme 1-18) (Metwally et al., 2011). 
 
 




Scheme 1-17  Synthesis of 4-arylthiosemicarbazides 
 
 
Scheme 1-18  Synthesis of thiosemicarbazide derivatives from carbohydrazines 
 
Substituted phenylthiosemicarbazides were synthesiszed by nucleophilic addition between 
aromatic isothiocyanates and hydrazine (Bečka et al., 2017). A proposed mechanism for the 
reaction involves nucleophilic attack by hydrazine on the carbon of the isothiocyanate followed 
by proton transfer, resulting in the formation of phenylthiosemicarbazides (Scheme 1-19).   
 
 
Scheme 1-19  Postulated mechanism for thiosemicarbazide formation 
 
This reaction was carried out in protic solvents such as ethanol under both under reflux (for 7 
hours) (Foroughifar et al., 2014), and at  room temperature (for 30 mins) (Benmohammed et 
al., 2014). Water can also be used with hydrochloric acid as a catalyst for selected 
thiosemicarbazides such as 1-(2-hydroxybenzoyl) thiosemicarbazide at 95 °C for 4 hours 
(Nurkenov et al., 2016). 
  
This moiety also reacts with compounds containing C=O and C=N groups to form a variety of 
five or six membered heterocyclic molecules, including thiazoles, pyrazoles, thiadiazoles, 
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triazoles, oxadiazoles and thiazines, which have shown potential biological activities 
(Metwally et al., 2011; Gazieva and Kravchenko, 2012; Singhal et al., 2013). 
 
1.3 Quinoline thiosemicarbazone hybrids 
Quinoline thiosemicarbazide hybrid molecules contain both quinoline and thiosemicarbazone 
moieties (Figure 1.5).  The thiosemicarbazone moiety can be linked to the quinoline 
framework at a variety of positions.  These molecules have shown  anti-tubercular (Patel et al., 
2014), anticancer (Huang et al., 2010), antimalarial (Pingaew et al., 2010), antifungal (Abdel-
Moty et al., 2005; Degola et al., 2015) and anticonvulsant (Singh et al., 2011) activity.  The Cu 
(II) and Ni (II) complexes of quinoline-2-carboxaldehyde thiosemicarbazone derivatives were 
also shown to have anticancer and antifungal activity (Kulkarni et al., 2010; Bisceglie et al., 
2015).  5-Acetyl (or 5 benzoyl)-8-hydroxyquinoline-4-phenyl thiosemicarbazones and 2-
hydroxyquinoline-3-thiosemicarbazones were tested for the antibacterial activity, but proved 
to be mildy active or inactive against the bacterial strains tested against (Abdel-Moty et al., 
2005; Kulkarni et al., 2010).  There have been no reports on the antibacterial activity of 
quinoline-2-thiosemicarbazones in the literature. 
 
 
Figure 1.5  The structure of a quinoline-thiosemicarbazone hybrid 
 
These molecules have been prepared by a condensation reaction between quinoline-2-
carboxaldehyde and thiosemicarbazides (Scheme 1-20) (Biscegli et al., 2015; Degola et al., 
2015; Huang et al., 2010). The reaction is quick and simple and occurs by adding equimolar 
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quantities of the thiosemicarbazide and quinoline-2-carbaldehyde in methanol or ethanol at 
room temperature with a few drops of glacial acetic acid to catalyse the reaction and left to stir 
in an ice bath for 20 hours (Bisceglie et al., 2015; Degola et al., 2015).  Variations of the 
synthesis involve changing the solvent to isopropanol and duration of the reaction (2-8 hours) 
(Huang et al., 2010). 
 
 
Scheme 1-20  Condensation reaction of quinoline-2-carbaldehyde with thiosemicarbazides  
 
A similar acid catalysed (HCl) condensation reaction between quinoline with ketone 
substituent at C-5 and thiosemicarbazide has also been reported (Scheme 1-21) (Abdel-Moty 
et al., 2005). In this reaction, alkanoyl chlorides were first reacted with 8-hydroxyquinoline to 
functionalise C-5 with a ketone from which quinoline-thiosemicarbazones were formed.   
 
 
Scheme 1-21  Synthesis of 8-hydroxyquinoline bearing a thiosemicarbazone moiety 
  
Serda et al. (2010) used a microwave assisted reaction between quinolones and 
thiosemicarbazide in ethanol using polyphosphoric acid as a catalyst to synthesise quinoline-
thiosemicarbazones where the thiosemicarbazone moiety was directly attached to the quinoline 
skeleton rather than a functional group on the ring.  The quinoline substrate was first nitrated 
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in order to deactivate the aromatic quinoline system, making the amide carbonyl more reactive 
toward nucleophilic addition (Scheme 1-22). 
 
 
Scheme 1-22  Synthesis of quinoline-diylidene bearing a thiosemicarbazone moiety 
 
The proposed mechanism of thiosemicarbazone formation proceeds by nucleophilic attack of 
the thiosemicarbazide on quinoline-2-carboxyaldehyde.  This is followed by proton transfer 
and dehydration to form an imine (Scheme 1-23). 
 
 




1.4 Hypothesis and aims 
Hypothesis 
Since both the quinoline and thiosemicarbazide moieties each have good biological activity on 
their own, combining these two structural motifs into one molecule may enhance the activity 
that each of them have on their own.  Furthermore, synthesising novel molecules with each of 
these moieties may lead to a new drug with possible anticancer, anti-HIV, antimalarial, 
antitubercular and antibacterial activity. 
 
Aims  
1. To synthesise a small library of quinoline thiosemicarbazone derivatives, with varying 
functional groups on both the quinoline and thiosemicarbazide moieties. 
2. To characterise the synthesised compounds using NMR spectroscopy and mass 
spectrometry. 
3. To determine the antibacterial activity of the synthesised compounds. 
4. To conduct a structure activity relationship analysis of the synthesised compounds with 





Chapter 2. Results and Discussion 
2.1 Chemistry 
Fifteen 2-quinoline thiosemicarbazones (6a-o), of which 12 were novel (6b-e, g-j and l-o) were 
synthesised in a four-step reaction (Scheme 2-1).  The 2-methylquinolines were first 
synthesised from fluoro, chloro and bromo substituted anilines (1a-c) and crotonaldehyde 
under acidic conditions using the Doebner-von Miller reaction.  The Doebner-von Miller 
reaction was used since this is the most popular method to synthesise 2-methylquinolines 
(Gopaul et al., 2015).  The resultant 2-methylquinolines were oxidised immediately without 
further purification to the quinoline-2-carbaldehydes (3a-c), which were then purified.  The 
thiosemicarbazide intermediates 5a-e were formed by a nucleophilic addition reaction between 
hydrazine hydrate and para substituted isothiocynates and thereafter reacted with the 
carbaldehyde intermediates (3a-c) to form quinoline-2-thiosemicarbazone derivatives 6a-o by 
a condensation reaction in yields of between 55 to 65%. 
 
 
Scheme 2-1  Reaction scheme for the synthesis of quinoline-2-carboxaldehyde 
thiosemicarbazone derivatives 6a-o 
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Characterisation of the 6-chloroquinoline-2-carbaldehyde intermediates (3a-c) 
The intermediates were characterised by 1H and 13C NMR spectroscopy as well as 2D NMR 
spectroscopy. For example, the 6-chloroquinoline-2-carbaldehyde (3b) showed six proton 
resonances in the 1H NMR spectrum, a sharp singlet at  10.17 assigned to the aldehyde group, 
and two olefinic doublets at  8.19 and  8.01 with J values of 8.5 Hz.  The H-5, H-7 and H-8 
resonances appeared at  7.86 (J = 2.2 Hz), 7.73 (J = 9.0, 2.2 Hz) and 8.16 (J = 9.0 Hz) as a 
doublet, double doublet and doublet respectively (Figure 2.1).  
 
 
Figure 2.1  1H NMR spectrum for 6-chloroquinoline-2-carbaldehyde 3b 
 
The 13C NMR spectrum showed the presence of ten carbon resonances, which includes the 
aldehyde carbon at  193.4 and five aromatic methine carbon resonances at  118.3 (C-3), 
136.4 (C-4), 126.6 (C-5), 131.6 (C-7) and 132.0 (C-8).  The remaining four carbon resonances 
were quaternary, the most deshielded being C-2 at  152.7, adjacent to the aldehyde and the 
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nitrogen atom, followed by C-8a at  146.3, adjacent to only the nitrogen and then followed by 
C-4a and C-6 at  136.4 and  130.6 respectively (Figure 2.2).   
 
Figure 2.2  13C NMR spectrum of 6-chloroquinoline-2-carbaldehyde (3b) 
 
H-5, H-7 and H-8 could be assigned by their splitting patterns and coupling constants.  H-5 is 
a doublet with a 2.2 Hz coupling to H-7, which appears as a double doublet with an additional 
9.0 Hz coupling to H-8 appearing as a doublet.  However, H-4 was assigned due to a HMBC 
correlation to C-8a.  Its coupled resonance was assigned to H-3.  The quaternary C-4a was 
assigned to  135.2 due to a HMBC with H-3 (Figure 2.3).  The remaining quaternary 
resonance at  130.6 was assigned to C-6.  The other halogenated quinoline-2-carbaldehydes 
were elucidated in a similar manner.   
 
Figure 2.3  Selected HMBC correlations for 3b used for the structural assignment  
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In 3a, the splitting pattern of H-5, H-7 and H-8 becomes rather complex, due to the presence 
of the 6-fluoro group.  H-5 is now a double doublet with JH5,F = 8.6 Hz and JH5,H7 = 2.8 Hz, H-
7 is a doublet of doublet of doublets (ddd) with JH7,F = 8.2 Hz, JH7,H8 = 9.2 Hz and JH5,H7 = 2.8 
Hz and H-8 appeared as a double doublet (JH7,H8 = 9.2 Hz and JH8,F = 5.0 Hz) (Figure 2.4).  
Changes in the 13C NMR spectrum were also evident due to the presence of fluorine.  The C-6 
resonance was seen as a doublet with a large J value of 253.0 Hz at  162.0, the ortho carbon 
resonances were doublets with smaller coupling constants of 26.1 Hz (C-7 at  121.1) and 22.0 
Hz (C-5 at  111.0) and the meta carbon resonances appeared at  133.2 and 131.0 as doublets 
with J values of 9.6 and 10.5 Hz respectively (Figure 2.5).  
 
  




Figure 2.5  13C-NMR spectrum for compound 3a 
 
Since the quinolines were reaction intermediates, it was found that the yields could be 
maximised by using the methylquinoline reaction mixture directly (without isolating it) in the 
oxidation reaction with selenium dioxide as an oxidant to form the desired quinoline-2-
carboxyaldehydes 3a-c. The reaction was monitored to completion using thin layer 
chromatography.  The yields of the substituted quinoline-2-carboxyaldehydes ranged from 55-
65%.  It was found that chloro and bromo substituents at C-6 on the quinoline moiety have 
higher oxidation yields (63-65%) than when a fluoro group is present at the same position 
(55%), probably due to the high electronegativity of fluorine, making the nitrogen on the 
quinoline ring less nucleophilic.  This affects the nucleophilic addition to the selenium in the 
first instance. The mechanism for this reaction is shown in Scheme 1-16 on page 12. 
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Synthesis and characterisation of the thiosemicarbazides 5a-e 
The thiosemicarbazides 5a-e were obtained in good yields (80 to 90%) by a straight forward 
nucleophilic addition reaction between hydrazine hydrate and various para substituted 
isothiocynates in isopropanol at ambient temperature.  The mechanism for this reaction is 
shown in Scheme 1-19 on page 14.  These compounds crystallised out of solution upon 
completion of the reaction.  Their 1H NMR spectra were recorded and their structures 
confirmed by mass spectroscopy.  
 
The NMR spectrum of a typical phenyl thiosemicarbazide, for example 5a contained the 
aromatic resonances H-2/6 at 7.64 (d, J = 7.5 Hz), H-3/5 at 7.29 (t, J = 7.5 Hz) and H-4 at 
7.09 (t, J = 7.5 Hz).  The NH2 proton resonance integrating to two protons appeared at  4.79 
and H-1' and H-3', the two NH protons, appeared at 9.11 as a sharp singlet and 9.64 as a broad 
singlet.  These two resonances are interchangeable.  The HMBC spectrum showed no 
correlation between NH-1 and H-2/6, which would have allowed these two resonances to be 
distinguished (Figure 2.6).   
 
Figure 2.6  1H NMR spectrum for phenyl thiosemicarbazide 5a 
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The mass spectra of all the compounds 5a-e contained the molecular ion peak, which indicated 
that the hydrazide had formed.  For example, in 5a, a mass at m/z 168 was obtained. 
 
The desired substituted quinoline-2-thiosemicarbazone derivatives 6a-o were obtained via a 
simple condensation reaction between the quinoline aldehydes 3a-c and the para substituted 
thiosemicarbazides 5a-e (Table 2-1). The resulting quinoline-2-thiosemicarbazone derivatives 
were obtained in good yields (59 to 80%). Similar compounds were synthesised previously 
using the same condensation reaction (Biscegli et al., 2015; Huang et al., 2010), however the 
compounds in this work, 6a-o differ from those synthesised previously in that they have 
substitution on the quinoline scaffold as well as para substituted phenylthiosemicarbazides 
used for the first time to form novel derivatives. The mechanism for this reaction is shown in 
Scheme 1-23 on page 17.   
Table 2-1  The yields of the synthesised quinoline-2-thiosemicarbazone derivatives 
Compound 6 R1 R2 Melting point °C Yield % 
a F H 193-210 75 
b F F 200-210 61 
c F Cl 188-193 67 
d F CH3 185-195 82 
e F NO2 195-205 72 
f Cl H 205-210 68 
g Cl F 215-225 62 
h Cl Cl 185-205 65 
i Cl CH3 198-205 80 
j Cl NO2 205-214 64 
k Br H 190-205 70 
l Br F 215-220 60 
m Br Cl 205-220 66 
n Br CH3 212-220 76 
o Br NO2 208-219 59 
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In general, the yield for the thiosemicarbazides with electron withdrawing groups were lower 
than those with electron donating groups.  The synthesised compounds were then characterised 
by NMR and mass spectroscopy.  
 
The 1H NMR spectrum of 6f containing a chloro group at position 6, had resonances similar to 
both of the starting materials, 3b and 5a.  Two of the resonances are however worth noting, H-
9 and H-3.  H-9 is the imine singlet proton and occurs as the result of the condensation between 
the aldehyde and thiosemicarbazone.  This is an indication that the reaction was successful.  H-
3, which occurred at  8.01 in the carbaldehyde, now occurs more downfield at  8.66.  This 
indicates that the thiosemicarbazide moiety has decreased the electron density at C-3, probably 
by induction after introducing all the electronegative groups present in the thiosemicarbazide 
moiety.  The other resonance which had a slight shift was H-5, which shifted from  7.86 in 3b 
to  8.12 in 6f (Figure 2.7).  The reason for this cannot be explained.  Resonance and inductive 
effects were discussed, but a reasonable explanation could not be provided. 
 
The 13C NMR spectrum of 6f contained similar resonances to that of its precursors, 3b and 5a.  
There were slight differences in the chemical shifts, however none were worth noting with the 
exception of the aldehyde carbon in 3b at  193.3 now being absent and appearing as an imine 




Figure 2.7  Aromatic region of the 1H NMR spectrum for compound 6f 
 
 
Figure 2.8  13C NMR spectrum for compound 6f 
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2.2 Antibacterial activity of compounds 6a-o 
The synthesised compounds were tested for their antibacterial activity against six bacterial 
strains, two Gram +ve strains, Staphylococcus aureus and methicillin resistant Staphylococcus 
aureus (MRSA) and four Gram –ve strains, Escherichia coli, Pseudomonas aeruginosa, 
Salmonella typhimurium and Klebsiella pneumonia.   These gram negative bacteria are on the 
WHOs priority 1 (critical) list and the Staphylococcus species on the priority 2 (high) list for 
bacterial strains where new drugs are needed 
(www.who.int/mediacentre/news/releases/2017/bacteria-antibiotics-needed/en/).  
Pseudomonas is no. 2 on the critical list with the Enterobacteriaceae, such as Escherichia, 
Salmonella and Klebsiella being no. 3.  Staphylococcus aureus and MRSA is no. 2 on the high 
priority list. 
 
A disc diffusion assay was first used as a preliminary screening method to select compounds 
for further minimum bactericidal concentration (MBC) tests.  Compounds 6c, 6g, 6h, 6l and 
6o showed activity against four or more strains (Table 2-2).  This set contained all compounds 
with a para substituted fluoro group on the thiosemicarbazide portion of the molecule 6c, 6g 
and 6l.  These three compounds were also active against both S. aureus and MRSA.  
 
Compound 6h (with a 6-Cl, 4'-Cl substitution pattern) was active in all four of the Gram –ve 
bacterial strains. The activity was lost when a fluoro group replaced the chloro group at C-4' 
(6g), resulting in loss of activity with E. coli, however this resulted in added activity with 
MRSA.  The compound with a bromo group at C-6 and methyl group at C-4' (6o) had the least 
activity among these five compounds, showing activity in four of the bacterial strains when the 
other four compounds showed activity in five of the bacterial strains.   Thus, the best lead for 
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antibacterial activity was fluoro substitution at the para position of the thiosemicarbazide 
moiety. 
 




  Diameter of zone inhibition (mm) 
 Substituents    Gram-Positive  Gram-negative 
Compound R1 R2  Sa MRSA  Ec Pa St Kp 
6a F H  _ 17  _ 15 _ _ 
6b F F  _ 15  _ 14 _ _ 
6c F Cl  15 14  15 15 15 _ 
6d F NO2  _ 13  _ 13 _ 13 
6e F CH3  _ _  _ 15 15 15 
6f Cl H  _ 15  _ 15 _ _ 
6g Cl F  14 15  _ 15 15 15 
6h Cl Cl  14 _  14 16 15 15 
6i Cl NO2  _ _  _ _ _ _ 
6j Cl CH3  14 15  _ _ _ 15 
6k Br H  _ 15  _ _ 15 _ 
6l Br F  15 15  _ 13 16 14 
6m Br Cl  _ _  _ _ 14 14 
6n Br NO2  _ _  _ _ 16 _ 
6o Br CH3  15 _  _ 16 14 15 
Sa = Staphyllococcus areus; MRSA = Methicillin resistant Staphyloccocus areus; Ec = Escherichia coli; Ps = 
Pseudomonas aeruginosa; St = Salmonella typhimurium; Kp = Klebsiella pneumonia. 
 
 
The five compounds (6c, 6l, 6g, 6h and 6o) showing activity in four or more bacterial strains 
were then diluted to different concentrations and spotted directly on agar plates containing the 
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different microorganisms to determine their MBC values.  This method was used since the 
compounds were insoluble in aqueous media and precipitated out on trying the broth dilution 
method.  Unfortunately, most of the compounds had MBC values of > 625 µM, with the 
exception of 6l, containing a 6-Br substitutent and fluoro group at the para position of the 
thiosemicarbazide moiety (Table 2-3).  Thus, the larger and more polarisable bromo group on 
the quinoline scaffold was essential for this antimicrobial activity as when the smaller chloro 
and fluoro groups occupy the same position, activity is decreased.   
 
Table 2-3  Minimum bactericidal concentration (MBC in µM) of selected quinoline-2-
thiosemicarbazone derivatives 
   Gram +ve strain  Gram –ve strain 
Compound  R1 R2     Sa MRSA  Ec Pa St Kp 
6c F  Cl > 625 > 625  > 625 > 625 > 625 > 625 
6l Br F    387    387  > 625 > 625 > 625 > 625 
6g Cl F > 625 > 625  > 625 > 625 > 625 > 625 
6h Cl Cl > 625 > 625  > 625 > 625 > 625 > 625 
6o Br CH3 > 625 > 625  > 625 > 625 > 625 > 625 
Ciprofloxacin       94.3  188.6  2.95 188.6 2.95 11.8 
Levofloxacin      21.6    86.5  0.34 345 21.6 21.6 
Sa = Staphyllococcus areus; MRSA = Methicillin resistant Staphyloccocus areus; Ec = Escherichia coli; Ps = 
Pseudomonas aeruginosa; St = Salmonella typhimurium; Kp = Klebsiella pneumonia. 
 
 
It was already established from the disc diffusion assays that fluoro substitution on the 
thiosemicarbazide moiety resulted in antimicrobial activity.  Thus, the 6-Br, 4'-F substitution 
pattern on these quinoline-2-thiosemicarbazides was the best substitution pattern on this 
particular quinoline-thiosemicarbazide scaffold for antibacterial activity against 
Staphylococcus aureus and MRSA to occur.  However, the results were not comparable to the 
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standard antibiotics, ciprofloxacin and levofloxacin (Table 2-3), hence cell viability and 
cytotoxicity studies on 6l were not carried out.  
 
Our results corroborated findings by Kulkarni et al. (2010) and Abdel-Moty et al. (2005) who 
also found that 5-Acetyl (or 5 benzoyl)-8-hydroxyquinoline-4-phenyl thiosemicarbazones and 
2-hydroxyquinoline-3-thiosemicarbazones showed weak to no activity in the bacterial strains 
tested against.  However, 6l (6-Br, 4'-F derivative) did show interesting antibacterial activity 
and further research on this particular molecule, perhaps by adding other groups to the molecule 
using this as a basic scaffold can be determined in order to identify a compound that can be 
developed into a potential antibiotic.  
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Chapter 3. Experimental 
3.1 General Experimental Procedures 
Chemicals and reagents used in this study were purchased from Sigma-Aldrich through Capital 
Laboratories, South Africa.  Organic solvents were redistilled according to standard 
procedures.  TLC analysis was carried out on silica gel 60 F254 plates purchased from Merck 
South Africa. Purifications were carried out by column chromatography using silica gel (60- 
120 mesh) as the stationery phase and varying ratios of ethyl acetate and hexane as the mobile 
phase.  IR spectra were recorded using a Perkin Elmer 100 FT-IR spectrometer.  1H, 13C and 
2D NMR experiments were carried out in DMSO-d6 using a Bruker Avance 400 MHz 
instrument. Tetramethylsilane (TMS) was used as the internal standard with chemical shifts 
reported in (ppm) and coupling constants (J) in Hz, referenced to the DMSO-d6 solvent line 
(2.50 ppm for 1H and 39.52 ppm for 13C). Spectra were analysed using Topspin 3.1 software 
(2013). High-Resolution mass spectral data (HRMS) were obtained at ambient temperature 
using a Bruker micro TOF-Q II ESI instrument. Melting points were carried out on a Stuart 




Synthesis of 6-substituted quinoline-2-aldehyde derivatives 3a-c 
The respective para substituted anilines 1a-c (40.0 mmol) were reacted with crotonaldehyde 
(60.0 mmol, 5.00 mL) in 40 mL of HCl:H2O (1:1) under reflux at 100 °C for 12 h. The reaction 
was monitored by TLC. Upon completion, the mixture was basified with NaHCO3 to pH 8 and 
NaCl added to the mixture, which was subsequently extracted with EtOAc (3 × 60 mL). The 
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mixture was then dried over anhydrous Na2SO4 and concentrated using a rotary evaporator to 
yield the crude 2-methylquinoline intermediates 2a-c as brown gummy residues.  These 
intermediates were not purified, but were oxidized directly using SeO2 (5.00 g, 40.0 mmol) in 
15 mL of 1,4-dioxane. Selenium dioxide was added gradually over a period of 5 min and the 
reaction left to stir under reflux at 110 °C for 1.5 h to produce the 6-substituted quinoline-2-
aldehydes 3a-c (Scheme 3-1). The reaction was monitored by TLC until completion. Once 
cooled, the reaction mixture was filtered through celite, diluted with water and extracted with 
ethyl acetate. The organic extract was dried over anhydrous MgSO4, concentrated and 
subjected to column chromatography on silica gel using a mobile phase of hexane:ethyl acetate 
(95:5) in yields of between 55 to 65%.  
 
 
Scheme 3-1  Reactions for the synthesis of 6-substituted quinoline-2-aldehydes 3a-c 
 
6-fluoroquinoline-2-carbaldehyde (3a); Orange solid residue; 55% yield; 1H NMR (DMSO-
d6, 400 MHz) 10.18 (s, H-9), 8.25 (1H, d, J = 8.5 Hz, H-4), 8.24 
(1H, dd, J = 9.2, 5.0 Hz, H-8), 8.03 (1H, d, J = 8.5 Hz, H-3), 7.58 
(1H, ddd, J = 9.2, 8.2, 2.8 Hz, H-7), 7.50 (1H, dd, J = 8.6, 2.8 Hz, 
H-5); 13C NMR (DMSO-d6, 100 MHz)193.4 (C-9), 162.0 (d, JCF = 253.0 Hz, C-6), 152.2 (d, 
JCF = 2.9 Hz, C-2), 145.0 (C-8a), 136.7 (d, JCF = 5.6 Hz, C-4), 133.2 (d, JCF = 9.6 Hz, C-8), 
131.0 (d, JCF = 10.5 Hz, C-4a), 121.1 (d, JCF = 26.1 Hz, C-7), 118.1 (C-3), 111.0 (d, JCF = 22.0 
Hz, C-5).  
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6-chloroquinoline-2-carbaldehyde (3b); Cream white; 65% yield; 1H NMR (DMSO-d6, 400 
MHz)  10.17 (s, H-9), 8.20 (1H, d, J = 8.5 Hz, H-4), 8.16 (1H, d, 
J = 9.0 Hz, H-8), 8.01 (1H, d, J = 8.5 Hz, H-3), 7.86 (1H, d, J = 2.2 
Hz, H-5), 7.73 (1H, dd, J = 9.0, 2.2 Hz, H-7); 13C NMR (DMSO-
d6, 100 MHz)  193.3 (C-9), 152.7 (C-2), 146.3 (C-8a), 136.4 (C-4), 135.2 (C-4a), 132.0 (C-
8), 131.6 (C-7), 130.6 (C-6), 126.6 (C-5), 118.3 (C-3). 
 
6-Bromoquinoline-2-carbaldehyde (3c); light brown solid residue; 63% yield;  1H NMR 
(DMSO-d6, 400 MHz) 10.18 (s, H-9), 8.20 (1H,d, J = 8.5 Hz, H-
4), 8.10 (1H, d, J = 9.0 Hz, H-8), 8.04 (1H, d, J = 2.1 Hz, H-5 ), 
8.02 (1H, d, J = 8.5 Hz, H-3), 7.86 (1H, dd, J = 9.0, 2.3 Hz, H-7); 13C NMR (DMSO-d6, 100 
MHz) 193.3 (C-9), 152.8 (C-2), 146.5 (C-8a), 136.4 (C-4), 134.1 (C-8), 132.0 (C-7), 131.0 
(C-4a), 130.0 (C-5), 123.6 (C-6), 118.3 (C-3). 
 
Synthesis of para substituted phenylisothiosemicarbazides 5a-e 
Para substituted phenylisocynates 4a-e (6.70 mmol) were dissolved in isopropanol (10 mL), 
to which hydrazine hydrate (0.66 mL, 13.40 mmol) was added and the mixture stirred for 15 
min at room temperature and then placed in an ice-bath for 30 min. The crystals that formed 
were filtered and washed with isopropanol to yield the phenylisothiosemicarbazides 5a-e in 
yields of between 82 and 90% (Scheme 3-2). 
 
Scheme 3-2  The reaction of phenylisocyanates with hydrazine hydrate to produce 4-
substituted thiosemicarbazides 5a-e 
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N-phenylhydrazinecarbothioamide (5a); white solid residue: 90% yield:  1H NMR (DMSO-d6, 
400 MHz)  9.64 (s, 3'-NH), 9.11 (s, 1'-NH) 7.64 (2H, bd, J = 8.1 Hz, 
H-2/6), 7.29 (2H, dd, J = 8.1, 7.3 Hz, H-3/5), 7.09 (1H, t, J = 7.3 Hz, 
H-4), 4.79 (s, 4'-NH). 
 
N-(4-fluorophenyl) hydrazinecarbothioamide (5b); white solid residue: 86% yield: 1H NMR 
(DMSO-d6, 400 MHz)  9.60 (s, 3'-NH), 9.11 (s, 1'-NH), 7.60 (bs, 
H-2/6), 7.12 (2H, t, J = 8.9 Hz, H-3/5), 4.76 (s, 4'-NH). 
 
N-(4-chlorophenyl) hydrazinecarbothioamide (5c); white solid residue: 84% yield: 1H NMR 
(DMSO-d6, 400 MHz)  9.19 (s, 1'-NH), 7.68 (2H, bd, J = 8.7 Hz, 
H-2/6), 7.33 (2H, d, J = 8.7 Hz, H-3/5), 4.81 (s, 3'-NH). 
 
N-(4-nitrophenyl) hydrazinecarbothioamide (5d); yellow solid residue: 80% yield: 1H NMR 
(DMSO-d6, 400 MHz)  9.35 (s, 3'-NH), 8.13 (2H, d, J = 9.2 Hz, 
H-3/5), 7.80 (3H, bs, H-2/6, 1'-N-H), 4.45 (s, 4'-NH). 
 
N-p-tolylhydrazinecarbothioamide (5e); yellow solid residue: 88% yield: 1H NMR (DMSO-d6, 
400 MHz)  9.75 (s, 3'-NH), 7.41 (2H, d, J = 8.2 Hz, H-2/6), 7.10 
(2H, d, J = 8.2 Hz, H-7/9), 2.26 (s, CH3). 
 
Synthesis of quinoline-2-carboxyaldehyde thiosemicarbazone derivatives 6a-o 
Phenylthiosemicarbazides 5a-e (0.482 mmol) were dissolved in ethanol by heating slightly 
while stirring in an oil bath. The substituted quinoline aldehydes 3a-c (0.583 mmol) were then 
added separately to each of the dissolved phenylthiosemicarbazides (5a-e) and the resulting 
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mixture refluxed for 5 h at 110 °C. The reaction mixture was then placed in an ice bath for 30 
min, where the product crystallised out and was filtered to yield the products 6a-o in yields of 
between 59 and 80% (Scheme 3-3). 
 
 
Scheme 3-3  The reaction of quinoline-2-carbaldehydes and thiosemicarbazides to form 
quinoline-2-carboxaldehyde thiosemicarbazone derivatives 6a-o 
 
(E)-2-((6-fluoroquinolin-2-yl)methylene)-N-phenylhydrazine carbothioamide (6a); light 
yellow solid: 75% yield: mp 193-210 °C: UV λmax 
(EtOAc) nm (log ɛ) 250 (4.24), 287 (4.15), 326 (4.13), 
341 (4.16), 355 (4.20); IR (KBr) max: 3317 (N-H), 3105 (C-H), 2939 (C-H), 1542 (C=C), 1498 
(C=C), 1181 (C-F) cm-1; 1H NMR (DMSO-d6, 400 MHz)  12.20 (s, 11-NH), 10.38 (s, 13-NH), 
8.65 (1H, d, J = 8.8 Hz, H-3), 8.38 (1H, d, J = 8.8 Hz, H-4), 8.33 (s, H-9), 8.10 (1H, dd, J = 
9.2, 5.5, Hz, H-8), 7.80 (1H, dd, J = 9.3, 2.8 Hz, H-5), 7.70 (1H, ddd, J = 9.2, 8.9, 2.8 Hz, H-
7), 7.56 (2H, d, J = 7.8 Hz, H-2'/6') , 7.41 (2H, t, J = 7.8 Hz, H-3'/5'), 7.25 (1H, t, J = 7.8 Hz, 
H-4'); 13C NMR (DMSO-d6, 100 MHz) 176.6 (C-12), 160.0 (d, JCF = 245.2 Hz, C-6), 153.4 
(d, JCF = 2.5 Hz, C-2), 144.5 (C-8a), 142.7 (C-9), 138.9 (C-1'), 135.8 (d, JCF = 5.0 Hz, C-4), 
131.6 (d, JCF = 9.4 Hz, C-8), 128.7 (d, JCF = 10.3 Hz, C-4a), 128.1 (C-2'/6'), 126.3 (C-3'/5'), 
125.7 (C-4'), 119.9 (d, J = 25.8 Hz, C-7), 119.2 (C-3), 111.2 (d, J = 21.9 Hz, C-5). 
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(E)-N-(4-fluorophenyl)-2-((6-fluoroquinolin-2-yl)methylene)hydrazine carbothioamide(6b); 
yellow solid residue: 78% yield: mp 200-210 °C: 
UV λmax (Ethylacetate)nm (log ɛ) 250 (4.24), 326 
(4.31), 340 (4.35), 354 (4.37); IR (KBr) max: 3302 (N-H), 3117 (C-H), 2977 (C-H), 1504 
(C=C), 1176 (C-F) cm-1 ;1H NMR (DMSO-d6, 400 MHz)  12.22 (s, 11-NH), 10.37 (s, 13-NH), 
8.64 (1H, d, J = 8.8 Hz, H-3), 8.39 (1H, d, J = 8.8 Hz, H-4 ), 8.32 (s, H-9), 8.10 (1H, dd, J = 
8.8, 5.5, Hz, H-8), 7.80(1H, dd, J = 9.3, 2.8 Hz, H-5), 7.70 (1H, ddd, J = 8.8, 8.8, 2.9 Hz, H-
7), 7.55 (2H, dd, J = 8.9 ,5.1 Hz, H-2'/6'), 7.24 (2H, dd, J = 8.8, 8.8 Hz, H-3'/5'); 13C-
NMR(DMSO-d6, 100 MHz)  176.9 (C-12), 160.1 (d, JCF = 245.1 Hz, C-6), 159.9 (d, JCF = 
241.3 Hz, C-4'), 153.4 (d, JCF = 2.7 Hz, C-2), 144.5 (C-8a), 142.9 (C-9), 135.8 (d, JCF = 5.1 Hz, 
C-4), 135.2 (C-1'), 131.6 (d, JCF = 9.3 Hz, C-8), 128.7 (d, JCF = 10.6 Hz, C-4a), 128.5 (d, J = 
8.4 Hz, C-2'/6'), 119.9 (d, JCF = 25.5 Hz, C-7), 119.1 (C-3), 114.8 (d, J = 22.3 Hz, C-3'/5'), 
111.2 (d, J = 21.7 Hz, C-5); HRMS(pos) (m/z): calculated for C17H12F2N4S (M + H)+: 341.0672, 
found: 341.0680. 
 
(E)-N-(4-chlorophenyl)-2-((6-fluoroquinolin-2-yl)methylene)hydrazine carbothioamide (6c); 
yellow solid residue: 67% yield: mp 188-193 °C: UV 
λmax (Ethylacetate)nm (log ɛ) 249 (4.29), 326 (4.39), 
340 (4.33), 354 (4.44); IR (KBr) max: 3303 (N-H), 3118 (C-H), 2972 (C-H), 1503 (C=C), 1177 
(C-F) cm-1; 1H NMR (DMSO-d6, 400 MHz) 12.27 (s, 11-NH), 10.40 (s, 13-NH), 8.63 (1H, d, 
J = 8.8 Hz, H-3), 8.39 (1H, d, J = 8.8 Hz, H-4 ), 8.33 (s, H-9), 8.10 (1H, dd, J = 8.8, 5.5, Hz, H-
8), 7.80 (1H, dd, J = 9.3, 2.8 Hz, H-5), 7.70 (1H, ddd, J = 8.8, 8.8, 2.9 Hz, H-7), 7.61 (1H, dd, 
J = 8.9 ,5.1 Hz, H-2'/6') , 7.46 (1H, dd, J = 8.8, 8.8 Hz, H-3'/5'); 13C-NMR (DMSO-d6, 100 MHz) 
176.6 (C-12), 160.1 (d, JCF = 245.1 Hz, C-6), 153.3 (C-2), 144.5 (C-8a), 143.1 (C-9), 137.9 
(C-1'), 135.8 (d, JCF = 4.9 Hz, C-4), 131.7 (d, JCF = 9.3 Hz, C-8), 129.7 (C-4'), 128.7 (d, JCF = 
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10.6 Hz, C-4a), 128.0 (C-3'/5'), 127.9 (C-2'/6'), 119.9 (d, JCF = 25.6 Hz, C-7), 119.2 (C-3), 111.2 
(d, JCF = 22.0 Hz, C-5); HRMS(pos) (m/z): calculated for: C17H12ClFN4S (M-H)+: 358.05, 
found: 357.081. 
 
(E)-2-((6-fluoroquinolin-2-yl)methylene)-N-(4-nitrophenyl)hydrazine carbothioamide (6d); 
yellow solid residue: 82% yield: mp 200-210 °C: 
UV λmax (Ethylacetate) nm (log ɛ) 249 (4.30), 
330 (4.67), 344 (4.62); IR ʋmax 3359 (N-H), 3083 (C-H), 2927 (C-H), 1702*, 1596 (C=C), 1529, 
1499, 1485, 1322, 1299, 1222, 1153, 1106 (C-F) cm-1;1H-NMR(DMSO-d6, 400 MHz)  11.49 
(s, 11-NH), 9.71 (s, 13-NH), 8.56 (1H, d, J = 8.8 Hz, H-3), 8.42 (1H, d, J = 8.8 Hz, H-4), 8.24 
(d, J = 9.3 Hz, H-3'/5'), 8.17 (s, H-9), 8.08 (1H, dd, J = 9.1, 5.4 Hz, H-8), 8.01 (d, J = 9.3, Hz, 
H-2'/6'), 7.82 (1H, dd, J = 9.4, 2.9 Hz, H-5) , 7.69 (1H, ddd, J = 9.1, 8.9, 2.9 Hz, H-7); 13C-NMR 
(DMSO-d6, 100 MHz) 160.0 ( d, JCF = 244.7 Hz, C-6), 153.2 (d, JCF = 2.8 Hz, C-2), 152.4 (C-
12), 145.6 (C-4'), 144.5 (C-8a), 142.3 (C-9), 141.7 (C-1'), 135.8 (d, JCF = 5.0 Hz, C-4), 131.6 
(d, JCF = 9.4 Hz, C-8), 128.6 (d, JCF = 10.4 Hz, C-4a), 124.7 (C-2'/6'), 119.9 (d, JCF = 25.6 Hz, 
C-7), 119.2 (C-3'/5'), 118.9 (C-3), 111.2 (d, JCF = 22.0 Hz, C-5). *These absorption bands only appear 
for the nitro substituted compounds, however the frequency is higher than usual for a nitro stretch, typically 
occurring at 1535-1600 cm-1. 
 
(E)-2-((6-fluoroquinolin-2-yl)methylene)-N-p-tolylhydrazine carbothioamide(6e); yellow 
solid residue: 72% yield: mp 186-195 °C: UV 
λmax (Ethylacetate)nm (log ɛ) 250 (4.27), 326 
(4.38), 340 (4.42), 354 (4.44); IR ʋmax 3300 (N-H), 3113 (C-H), 2962 (C-H), 1509 (C=C), 1178 
(C-F) cm-1;  1H-NMR (DMSO-d6, 400 MHz)  12.14 (s, 11-NH), 10.31 (s, 13-NH), 8.65 (1H, 
d, J = 8.8 Hz, H-3), 8.38 (1H, d, J = 8.8 Hz, H-4 ), 8.31 (s, H-9), 8.10 (1H,dd, J = 9.1, 4.9, Hz, 
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H-8), 7.80 (1H, dd, J = 9.3, 2.8 Hz, H-5), 7.70 (1H, ddd, J = 9.1, 8.9, 2.9 Hz, H-7), 7.41 (1H, 
d, J = 8.3, Hz, H-2'/6'), 7.20 (1H,d, J = 8.2 Hz, H-3'/5'); 13C-NMR (DMSO-d6, 100 MHz)  
176.6 (C-12), 160.0 (d, JCF = 246.5 Hz, C-6), 153.4 (d, JCF = 2.7 Hz, C-2), 144.5 (C-8a), 142.6 
(C-9), 136.3 (C-4'), 135.8 (d, JCF = 5.1 Hz, C-4), 134.8 (C-1'), 131.6 (d, JCF = 9.3 Hz, C-8), 
128.7 (C-4a), 128.6 (C-2'/6'), 126.2 (C-3'/5'), 119.9 (d, JCF = 25.9 Hz, C-7), 119.2 (C-3), 111.2 
(d, J = 21.7 Hz, C-5), 20.6 (C-7'); HRMS (m/z): calculated for: C18H15FN4S (M + Na)+: 338.10, 
found: 361.0901. 
 
(E)-2-((6-chloroquinolin-2-yl)methylene)-N-phenylhydrazine carbothioamide (6f); light 
yellow solid residue: 62% yield: mp 200-210 °C: UV 
λmax (Ethylacetate)nm (log ɛ) 250 (4.19), 270 (4.10), 330 
(4.16), 344 (4.22), 359 (4.25); IR ʋmax 3313 (N-H), 3110 (C-H), 2962 (C-H), 1532 (C=C), 1505, 
1487, 1250, 1186 (C-F) cm-1;1H-NMR (DMSO-d6, 400 MHz)  12.22 (s, 11-NH), 10.39 (s, 13-
NH), 8.66 (1H, d, J = 8.8 Hz, H-3), 8.37 (1H, d, J = 8.8 Hz, H-4), 8.32 (s, H-9), 8.12 (1H,d, J 
= 2.3, H-5), 8.04 (1H, d, J = 9.0 Hz, H-8), 7.79 (1H, dd, J = 9.0, 2.3 Hz, H-7), 7.56 (2H, d, J = 
7.7 Hz, H-2'/6'), 7.41 (2H, t, J = 7.8 Hz, H-3'/5'), 7.25 (1H, t, J = 7.4 Hz, H-4'); 13C NMR 
(DMSO-d6, 100 MHz)  176.6 (C-12), 154.3 (C-2), 145.8 (C-8a), 142.6 (C-9), 138.9 (C-1'), 
135.5 (C-4), 131.4 (C-4a), 130.8 (C-7), 130.4 (C-8), 128.6 (C-6), 128.1 (C-2'/6'), 126.7 (C-5), 
126.3 (C-3'/5'), 125.7 (C-4'), 119.4 (C-3). 
 
(E)-2-((6-chloroquinolin-2-yl)methylene)-N-(4-fluorophenyl)hydrazine carbothioamide (6g); 
yellow solid residue: 65% yield: mp 215-225°C: 
UV λmax(Ethylacetate) nm (log ɛ) 250 (4.42), 295 
(4.33), 384 (4.31); IR ʋmax 3301 (N-H), 3055 (C-H), 1511 (C=C), 1492, 1171 (C-F), 1067  cm-
1;1H NMR (DMSO-d6, 400 MHz)  12.24 (s, 11-NH), 10.38 (s, 13-NH), 8.65 (1H, d, J = 8.8 
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Hz, H-3), 8.38 (1H, d, J = 8.8 Hz, H-4), 8.32 (s, H-9), 8.12 (1H, d, J = 2.4 Hz, H-5), 8.04 (1H, 
d, J = 9.0 Hz, H-8), 7.79 (1H, dd, J = 9.0, 2.4 Hz, H-7), 7.55 (1H, dd, J = 8.9 ,5.1 Hz, H-2'/6') 
, 7.24 (1H, t, J = 8.8 Hz, H-3'/5'); 13C NMR (DMSO-d6, 100 MHz)  176.9 (C-12), 159.9 (d, 
JCF = 242.5 Hz, C-4'), 154.2 (C-2), 145.8 (C-8a), 142.7 (C-9), 135.5 (C-4), 135.2 (d, JCF = 2.6 
Hz, C-1'), 131.5 (C-4a), 130.8 (C-7), 130.4 (C-8), 128.6 (C-6), 128.5 (d, JCF = 8.3 Hz, C-2'/6'), 
126.7 (C-5), 119.4 (C-3), 114.8 (d, JCF = 22.4 Hz, C-3'/5'); HRMS (pos) (m/z): calculated for 
C17H12ClFN4S (M + H)+: 358.05, found: 358.0416. 
 
 (E)-N-(4-chlorophenyl)-2-((6-chloroquinolin-2-yl)methylene)hydrazine carbothioamide (6h); 
yellow solid residue: 80% yield: mp 185-205°C: 
UV λmax (Ethylacetate) nm (log ɛ) 250 (4.32), 330 
(4.44), 343 (4.50), 359 (4.53); IR ʋmax 3316 (N-H), 3133 (C-H), 2989 (C-H), 1588 (C=C), 1536, 
1509, 1488, 1190 (C-F), 1086 cm-1;1H-NMR (DMSO-d6, 400 MHz)  12.29 (s, 11-NH), 10.41 
(s, 13-NH), 8.64 (1H, d, J = 8.8 Hz, H-3), 8.38 (1H, d, J = 8.8 Hz, H-4), 8.32 (s, H-9), 8.12 
(1H, d, J = 2.4 Hz, H-5), 8.04 (1H, d, J = 9.0 Hz, H-8), 7.79 (1H, dd, J = 8.5, 2.3 Hz, H-7), 
7.60 (1H, d, J = 8.7 Hz, H-2'/6'), 7.46 (1H, d, J = 8.7 Hz, H-3'/5'); 13C-NMR (DMSO-d6, 100 
MHz)  176.6 (C-12), 154.2 (C-2), 145.8 (C-8a), 142.9 (C-9), 137.9 (C-1'), 135.6 (C-4), 131.5 
(C-4a), 130.8 (C-7), 130.4 (C-8), 129.7 (C-4'), 128.6 (C-6), 128.0 (C-2'/6'), 127.9 (C-3'/5'), 
126.7 (C-5), 119.4 (C-3); HRMS (pos) (m/z): calculated for :C17H12Cl2N4S (M + H)+: 374.02, 
found: 374.0122. 
 
 (E)-2-((6-chloroquinolin-2-yl)methylene)-N-(4-nitrophenyl)hydrazine carbothioamide (6i); 
yellow solid residue: 64% yield: mp 198-215 
°C: UV λmax (Ethylacetate) nm (log ɛ) 249 
(4.47), 321 (4.58), 334 (4.61), 349 (4.55); IR ʋmax 3364 (N-H), 3072 (C-H), 2921 (C-H), 1711*, 
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1598 (C=C), 1539, 1504, 1491, 1332, 1302, 1223, 1144, 1110 (C-F) cm-1;1H NMR (DMSO-d6, 
400 MHz)  11.52 (s, 11-NH), 9.71 (s, 13-NH), 8.57 (1H, d, J = 8.8 Hz, H-3), 8.42 (1H, d, J = 
8.8 Hz, H-4), 8.24 (1H, d, J = 9.3 Hz, H-3'/5'), 8.17 (s, H-9), 8.14 (1H, d, J = 2.4 Hz, H-5), 8.03 
(1H, d, J = 8.8 Hz, H-8), 8.02 (1H, d, J = 9.3 Hz, H-2'/6') , 7.79 (1H, dd, J = 9.0, 2.4 Hz, H-7); 
13C-NMR (DMSO-d6, 100 MHz)  154.1 (C-12), 152.2 (C-4'), 145.7 (C-2), 145.5 (C-8a), 142.1 
(C-9), 141.7 (C-1'), 135.6 (C-4), 131.4 (C-4a), 130.8 (C-7), 130.4 (C-8), 128.5 (C-6), 126.7 (C-
5), 124.7 (C-3'/5'), 119.2 (C-2'/6'), 119.1 (C-3). *These absorption bands only appear for the nitro 
substituted compounds, however the frequency is higher than usual for a nitro stretch, typically occurring at 1535-
1600 cm-1. 
 
(E)-2-((6-chloroquinolin-2-yl)methylene)-N-p-tolylhydrazine carbothioamide (6j); yellow 
solid residue: 80% yield: mp 198-205 °C: UV 
λmax (Ethylacetate) nm (log ɛ) 251 (4.40), 330 
(4.26), 360 (4.37); IR ʋmax 3348 (N-H), 3308, 3114 (C-H), 2964 (C-H), 1513 (C=C), 1250, 
1177 (C-F) cm-1 ;1H NMR (DMSO-d6, 400 MHz)  12.17 (s, 11-NH), 10.32 (s, 13-NH), 8.66 
(1H, d, J = 8.8 Hz, H-3), 8.37 (1H, d, J = 8.8 Hz, H-4 ), 8.31 (s, H-9), 8.12 (1H, d, J = 2.4 Hz, 
H-5), 8.04 (1H, d, J = 9.0 Hz, H-8), 7.79 (1H, dd, J = 9.0, 2.4 Hz, H-7), 7.41 (1H, d, J = 8.3 
Hz, H-2'/6'), 7.20 (1H, d, J = 8.3 Hz, H-3'/5'); 13C-NMR (DMSO-d6, 100 MHz)  176.6 (C-12), 
154.3 (C-2), 145.8 (C-8a), 142.4 (C-9), 136.3 (C-1'), 135.5 (C-4), 134.9 (C-4'), 131.4 (C-4a), 
130.8 (C-7), 130.4 (C-8), 128.6 (C-6), 128.0 (C-3'/5'), 126.6 (C-5), 126.2 (C-2'/6'), 119.4 (C-




(E)-2-((6-bromoquinolin-2-yl)methylene)-N-phenylhydrazine carbothioamide(6k); light 
yellow solid residue: 70% yield: mp 190-205 °C: UV 
λmax (Ethylacetate) nm (log ɛ) 249 (4.37), 331 (4.30), 
347 (4.35), 360 (4.40); IR ʋmax 3327 (N-H), 3139 (C-H), 2993 (C-H), 1533 (C=C), 1511, 1245, 
1188 (C-F), cm-1 ;1H-NMR (DMSO-d6, 400 MHz)  12.22 (s, 11-NH), 10.39 (s, 13-NH), 8.66 
(1H, d, J = 8.8 Hz, H-3), 8.37 (1H, d, J = 8.8 Hz, H-4), 8.32 (s, H-9), 8.28 (1H, d, J = 2.1 Hz, 
H-5), 7.97 (1H, d, J = 9.0 Hz, H-8), 7.89 (1H, dd, J = 9.0, 2.3 Hz, H-7), 7.56 (2H, d, J = 7.6 
Hz, H-2'/6'), 7.41 (2H, t, J = 7.8 Hz, H-3'/5'), 7.25 (1H, t, J = 7.4 Hz, H-4'); 13C-NMR (DMSO-
d6, 100 MHz)  176.6 (C-12), 154.3 (C-2), 146.0 (C-8a), 142.6 (C-9),138.9 (C-1'), 135.4 (C-4), 
133.0 (C-7), 130.9 (C-8), 129.9 (C-5), 129.1 (C-4a), 128.1 (C-2'/6'), 126.3 (C-3'/5'), 125.7 (C-
4'), 120.1 (C-6), 119.4 (C-3). 
 
(E)-2-((6-bromoquinolin-2-yl)methylene)-N-(4-fluorophenyl)hydrazine carbothioamide (6l); 
yellow solid residue: 60% yield: mp 215-220 °C: 
UV λmax (Ethylacetate) nm (log ɛ) 250 (4.42), 285 
(4.17), 310 (4.23), 361 (4.37); IR ʋmax 3303 (N-H), 3107 (C-H), 2973 (C-H), 1505 (C=C), 1176 
(C-F) cm-1 ;1H NMR (DMSO-d6, 400 MHz)  12.24 (s, 11-NH), 10.38 (s, 13-NH), 8.65 (1H, d, 
J = 8.8 Hz, H-3), 8.38 (1H, d, J = 8.8 Hz, H-4), 8.31 (s, H-9), 8.28 (1H, d, J = 2.1 Hz, H-5), 
7.97 (1H, d, J = 9.0 Hz, H-8), 7.90 (1H, dd, J = 9.0, 2.1 Hz, H-7), 7.54 (1H, dd, J = 9.0, 5.1 
Hz, H-2'/6'), 7.24 (1H, t, J = 8.7 Hz, H-3'/5'); 13C-NMR (DMSO-d6, 100 MHz)  176.9 (C-12), 
159.9 (d, JCF = 240.2 Hz, C-4'), 154.3 (C-2), 146.0 (C-8a), 142.7 (C-9), 135.4 (C-4), 134.2 (C-
1'), 133.0 (C-7), 130.9 (C-8), 129.9 (C-5), 129.1 (C-4a), 128.5 (d, JCF = 8.3 Hz, C-2'/6'), 120.1 
(C-6), 119.3 (C-3), 114.8 (d, JCF = 22.3 Hz,C-3'/5'); HRMS (pos) (m/z): calculated for 
C17H12BrFN4S (M + H)+: 402.00, found: 402.9850. 
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 (E)-2-((6-bromoquinolin-2-yl)methylene)-N-(4-chlorophenyl)hydrazine carbothioamide 
(6m); yellow solid residue: 66% yield: mp 205-
220 °C: UV λmax (Ethylacetate) nm (log ɛ) 228 
(4.70), 275 (4.58), 333 (4.48); IR ʋmax 3313 (N-H), 3284, 3129 (C-H), 2990 (C-H), 1510 (C=C), 
1176 (C-F) cm-1; 1H-NMR (DMSO-d6, 400 MHz)  12.29 (s, 11-NH), 10.41 (s, 13-NH), 8.64 
(1H, d, J = 8.8 Hz, H-3), 8.38 (1H, d, J = 8.8 Hz, H-4), 8.32 (s, H-9), 8.29 (1H, d, J = 2.1 Hz, 
H-5), 7.97 (1H, d, J = 9.0 Hz, H-8), 7.90 (1H, dd, J = 9.0, 2.3 Hz, H-7), 7.61 (1H, d, J = 9.0 
Hz, H-2'/6'), 7.46 (1H, d, J = 8.7 Hz, H-3'/5'); 13C NMR (DMSO-d6, 100 MHz)  176.6 (C-12), 
154.2 (C-2), 146.0 (C-8a), 142.9 (C-9), 137.9 (C-1'), 135.5 (C-4), 133.0 (C-7), 130.9 (C-8), 
129.9 (C-5), 129.7 (C-4'), 129.1 (C-4a), 128.0 (C-3'/5'), 127.9 (C2'/6'), 120.1 (C-6), 119.3 (C-
3); HRMS (pos) (m/z): calculated for C17H12BrClN4S (M + H)+: 417.97, found: 418.9957. 
 
 (E)-2-((6-bromoquinolin-2-yl)methylene)-N-(4-nitrophenyl)hydrazine carbothioamide (6n); 
yellow solid residue: 76% yield: mp 195-205 
°C: UV λmax (Ethylacetate) nm (log ɛ) 249 
(4.32), 323 (4.63), 334 (4.67), 349 (4.61); IR ʋmax 3366 (N-H), 3071 (C-H), 2914 (C-H), 1721*, 
1598 (C=C), 1539, 1504,  1333, 1145 (C-F) cm-1; 1H-NMR (DMSO-d6, 400 MHz)  11.52 (s, 
11-NH), 9.71 (s, 13-NH), 8.57 (1H, d, J = 8.8 Hz, H-3), 8.41 (1H, d, J = 8.8 Hz, H-4), 8.30 
(1H, d, J = 2.1 Hz, H-5), 8.24 (1H, d, J = 9.4 Hz, H-3'/5'); 8.16 (s, H-9), 8.01 (1H, d, J = 9.2 
Hz, H-2'/6'), 7.96 (1H, d, J = 9.0 Hz, H-8), 7.89 (1H, dd, J = 9.0, 2.2 Hz, H-7), 13C-NMR 
(DMSO-d6, 100 MHz)  154.1 (C-12), 152.4 (C-4'), 145.9 (C-2), 145.6 (C-8a), 142.1 (C-9), 
141.7 (C-1'), 135.5 (C-4), 133.0 (C-7), 130.9 (C-8), 130.0 (C-5), 129.0 (C-4a), 124.7 (C-3'/5'), 
120.0 (C-6), 119.2 (C-2'/6'), 119.1 (C-3).  *These absorption bands only appear for the nitro substituted 
compounds, however the frequency is higher than usual for a nitro stretch, typically occurring at 1535-1600 cm-
1. 
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(E)-2-((6-bromoquinolin-2-yl)methylene)-N-p-tolylhydrazine carbothioamide (6o); yellow 
solid residue: 59% yield: mp 212-220 °C: UV λmax 
(Ethylacetate) nm (log ɛ) 229 (4.71), 280 (4.64), 330 
(4.57); IR ʋmax 3309 (N-H), 3123 (C-H), 2963 (C-H), 1592 (C=C), 1537, 1514, 1485, 1249, 
1177 (C-F) cm-1;1H NMR (DMSO-d6, 400 MHz)  12.17 (s, 11-NH), 10.32 (s, 13-NH), 8.66 
(1H, d, J = 8.8 Hz, H-3), 8.37 (1H, d, J = 8.8 Hz, H-4), 8.31 (s, H-9), 8.28 (1H, d, J = 2.2 Hz, 
H-5), 7.97 (1H, d, J = 9.0 Hz, H-8), 7.90 (1H, dd, J = 9.0, 2.3 Hz, H-7), 7.41 (1H, d, J = 8.3 
Hz, H-2'/6'), 7.20 (1H, d, J = 8.2 Hz, H-3'/5'); 13C-NMR (DMSO-d6, 100 MHz)  176.6 (C-12), 
154.4 (C-2), 146.0 (C-8a), 142.4 (C-9), 136.3 (C-1'), 135.4 (C-4), 134.9 (C-4'), 133.0 (C-7), 
130.9 (C-8), 129.9 (C-5), 129.1 (C-4a), 128.6 (C-3'/5'), 126.2 (C2'/6'), 120.1 (C-6), 119.4 (C-
3), 20.6 (C-7'); HRMS (pos) (m/z): calculated for C17H12F2N4S (M + Na)+: 398.02, found: 
421.0108. 
 
3.3 In-vitro antimicrobial studies 
The antimicrobial activities of the synthesised compounds 6a-o were tested against two Gram 
+ve strains (Staphylococcus aureus ATCC 25923 and Methicillin resistant Staphylococcus 
aureus ATCC BAA-1683) and four Gram –ve strains (Escherichia coli ATCC 25922, 
Pseudomonas aeruginosa ATCC 27853, Salmonella typhimurium ATCC 14026 and Klebsiella 
pneumonia ATCC 314588) using levofloxacin and ciprofloxacin as standards for comparison. 
The disc diffusion method was used for initial screening.  Those compounds that showed a 
broad spectrum of activity across all the bacterial strains, showing activity in at least four of 
the six strains were chosen to determine their minimum bactericidal activity (MBC).   
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For the disc diffusion assay, the bacterial micro-organisms were grown overnight at 37 °C in 
nutrient broth (Biolab, South Africa) and adjusted to a 0.5 McFarland standard using distilled 
water.  Mueller-Hinton agar (MHA) (Biolab, South Africa) plates were prepared by dissolving 
38 g of agar in 1 L of water and pouring these into sterile petri dishes, which were then allowed 
to set and dry at room temperature.  They were then inoculated with the respective strains of 
bacteria by streaking a swab (dipped into the micro-organism solution) evenly over the entire 
sterile agar surface. A volume of 5 μL of a 10 mg mL-1 solution of each test compound was 
then impregnated onto antibiotic test discs (12 mm) and placed onto the Mueller-Hinton plates. 
They were then left to incubate for 24 hours at 37 °C, and the zones of inhibition measured in 
millimeters.  
 
For the determination of MBCs, a swab of the microbial cultures (adjusted to 0.5 McFarland) 
prepared as described previously were again evenly streaked over sterile agar plates. The test 
compounds were dissolved in DMSO and serially diluted in 1 mL Eppendorf tubes.  A volume 
of 5 μL of concentrations of 19.5 to 625 µg mL-1 were directly spotted on MHA plates 
containing the respective bacterial strains and incubated at 37 °C for 20 h to determine the 
MBCs. The MBC was the lowest concentration showing a zone of inhibition around the spotted 
compound.  DMSO was used as a control and showed no zones of inhibition to any of the 
bacterial strains tested against.  Levofloxacin and ciprofloxacin served as the standard drugs 




Chapter 4. Conclusion 
Fifteen 6-substituted quinoline-2-thiosemicarbazones were synthesised in good yields from a 
Doebner-von Miller reaction between para-substituted anilines and crotonaldehyde to form 
quinoline intermediates. Oxidation with SeO2 to form quinoline-2-carbaldehydes proved to be 
a useful method to functionalise the 2-position for further reactions and to hybridise the 
quinoline framework.  Formation of thiosemicarbazones was an easy derivatisation and way in 
which the quinolines could form quinoline thiosemicarbazone hybrid molecules.  Thus, the 
reaction sequence carried out was a good way of forming quinoline thiosemicarbazone hybrids 
which have the attributes of both quinolines and thiosemicarbazones. 
 
A full structural elucidation of all the compounds synthesised was carried out and will provide 
a basis for the identification of similar molecules in future research. The different substitution 
patterns were found to have an effect on the antibacterial activity of the compounds with 
compound 6l, containing a 6-Br substituent on the quinoline moiety and fluoro group at the 
para position of the thiosemicarbazide moiety showing the best antibacterial activity at 387 
µM.  Unfortunately, the antibacterial activity of the synthesised compounds were inactive as 
antibacterial agents even though the individual constituents, quinolines and 
thiosemicarbazones have previously demonstrated good antibacterial activity.  This could 
partly be due to the insolubility of the compounds in aqueous media. 
 
Future work will involve modifying the structure of 6l (6-Br, 4'-F derivative), by adding other 
groups to the molecule using this as a basic scaffold.  Compound 6l was the only compound 
that showed good antibacterial activity.  It is hoped that modifications of the structure will 
identify a compound that can be developed into a potential antibiotic.  The modifications can 
include groups that will increase the solubility of the product.  
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1H-NMR spectrum of compound 5a
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13C-NMR spectrum of compound 6f
48












































13C-NMR spectrum of compound 6g 53
HRMS of compound 6g 54




UV spectrum of compound 6g 55
IR spectrum of compound 6g 56

























13C-NMR spectrum of compound 6h 59
HRMS of compound 6h
60





UV spectrum of compound 6h 61
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